Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-14

Nrc Health (NRC) Stock Forecast Oct. 14, 2026

Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D ▲ Bullish Exact rating locked
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Top 35% of 4004 stocks scored
Rank correlation · 90D n/a No per-ticker sample yet
Market Cap $446M small-cap · #8 of 12 peers
Summary

Nrc Health (NRC) stock forecast summary

Our AI ranks Nrc Health outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Nrc Health is a small-cap company with a market capitalization of $446M. It ranks number 8 by market capitalization among the 12 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast. Its D/E Ratio of 19.79x is the highest of the 11 peers that report one.

A per-ticker accuracy statistic for NRC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, NRC included.

Follow NRC free
Price

NRC price chart and AI forecast

NRC
Cross-section · 2026-10-14

How NRC ranks among 4004 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals

Nrc Health (NRC) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.

Financial statement data is not available for this company: its filings are not in a form the pipeline converts, so only market data is shown.

Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.

Valuation & Market

MetricNRCIndustry medianRank
Market Cap $446M $1.12B 8/12

Profitability & Margins

MetricNRCIndustry medianRank
ROIC 14.6% 7.6% 5/12
Operating Margin 10.5% -125.8% 4/13
EBT Margin 6.7% -114.8% 5/13
Tax Rate 37.6% – –

Financial Health

MetricNRCIndustry medianRank
Current Ratio 0.65x 0.78x 11/16
D/E Ratio 19.79x 1.02x 1/11
Financial Leverage 20.79x 2.02x 1/11

Cash Flow

MetricNRCIndustry medianRank
FCF/Sales 15.5% -19.0% 2/8
CapEx/Sales 5.6% 2.8% 2/8

Operational Efficiency

MetricNRCIndustry medianRank
Asset Turnover 1.03x 0.56x 2/9
Receivables Turnover 15.0x 5.6x 1/7
Fixed Assets Turnover 3.5x 4.5x 6/9
Days Sales Outstanding 24 days 65 days 7/7

Dividend & Shareholder Information

MetricNRCIndustry medianRank
Shares Outstanding 22M – –
Quarterly Financial Reports

NRC quarterly financials and insider trading

Industry Peers · Services-Commercial Physical & Biological Research

Nrc Health (NRC) industry peers

Companies classified under the same SEC industry code as Nrc Health (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
NRC Nrc Health ▲ $446M – –
IQV Iqvia Holdings Inc. ▼ $43.51B 32.6x 7.3x
INCY Incyte Corp ▼ $21.70B 17.5x 4.5x
MEDP Medpace Holdings, Inc. ▶ $17.02B 34.6x 39.2x
CRL Charles River Laboratories International, Inc. ▼ $14.27B – 5.0x
ICLR Icon Plc ▶ $12.68B – 1.4x
ABSI Absci Corp ▲ $1.56B – 7.9x
OABI Omniab, Inc. ▲ $683M – 2.6x
MXCT Maxcyte, Inc. ▲ $100M – 0.6x
ONMD Onemednet Corp ▶ $24M – –
VSBC Vitaspring Biomedical Co. Ltd. ▼ $7M – –
BUDZ Weed, Inc. ▲ $3M – –
BIAF Bioaffinity Technologies, Inc. ▼ N/A – –
CBIH Cannabis Bioscience International Holdings, Inc. ▼ N/A – –
FOXO Foxo Technologies Inc. ▼ N/A – –
ISPC Ispecimen Inc. ▼ N/A – –

Where NRC sits on the market map

Industrial Applications and Services · Services-Commercial Physical & Biological Research
Explore the map →
News

Nrc Health (NRC) stock news

Loading...

FAQ

Nrc Health (NRC) stock forecast FAQ

What is the Nrc Health (NRC) stock forecast?

Our AI ranks Nrc Health outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

How accurate are Nrc Health stock predictions?

A per-ticker accuracy statistic for NRC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Nrc Health forecasts updated?

Nrc Health forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.

Which companies are Nrc Health's industry peers?

16 issuers in our coverage, NRC included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.